Small cell carcinoma

Small cell carcinoma (SmCC) of the head and neck is a poorly differentiated, high-grade neuroendocrine carcinoma characterized by aggressive local invasion and a strong propensity for regional and distant metastasis.[1][2] In the oral and maxillofacial region, SmCC may arise as a primary mucosal neoplasm of the oral cavity, a primary salivary gland malignancy, or a metastatic deposit from a pulmonary or other extrapulmonary primary.[1][3] The tumor is biologically analogous to small cell lung cancer (SCLC) and is managed with similar platinum-based chemoradiation protocols extrapolated from SCLC data, as no large controlled trials specific to the head and neck exist.[4][5] Imaging findings are nonspecific, typically presenting as an aggressive soft-tissue mass with or without osseous destruction.[6] Prognosis is poor, with five-year overall survival generally below 30%.[7][8]

Current Classification

The WHO/IARC consensus framework classifies neuroendocrine neoplasms into well-differentiated neuroendocrine tumors (NETs, grades 1–3) and poorly differentiated neuroendocrine carcinomas (NECs).[9] SmCC falls within the NEC category as the small cell type (SCNEC), which is high grade by definition, with mitotic rates >10 per 2 mm² and Ki-67 typically >20%.[9][10] The WHO 2024 classification of head and neck tumors maintains this framework for the upper aerodigestive tract and salivary glands.[11]

Accepted Names and Aliases

• Small cell neuroendocrine carcinoma (SCNEC, SNEC)
• Small cell carcinoma (SmCC, SCC — the latter abbreviation is discouraged because of confusion with squamous cell carcinoma)
• Poorly differentiated neuroendocrine carcinoma, small cell type

Salivary Gland Subclassification

In major salivary glands, SmCC has historically been subclassified into a neuroendocrine type (further divided into Merkel cell [CK20-positive] and pulmonary [CK20-negative] varieties) and a ductal type.[12][13] Current immunohistochemical evidence indicates that virtually all salivary SmCCs express at least one neuroendocrine marker, blurring the ductal/neuroendocrine distinction.[14]

Obsolete Terms

• "Oat cell carcinoma" — an older pulmonary term occasionally applied to extrapulmonary sites; no longer recommended.[1]

• SmCC accounts for approximately 0.3% of all head and neck cancers.[3][15]
• Within the head and neck, the most common primary sites are the larynx, salivary glands, and sinonasal region; the oral cavity is an uncommon site.[1][3][7]
• In salivary glands, SmCC represents less than 1% of malignant neoplasms.[14][16]
• Primary SmCC of the oral cavity is exceedingly rare, limited to individual case reports and small series.[4][17]
• Male predominance is consistent across series, with male-to-female ratios of approximately 2–3:1.[2][7][16]
• Peak incidence is in the sixth to eighth decades (median age ~65–74 years).[2][7][8][12]
• Tobacco use is a recognized risk factor, paralleling SCLC.[3][4]
• SmCC of the head and neck is approximately ten times more likely to originate from salivary glands than squamous cell carcinoma of the same region.[7]

Presentation and Symptoms

• Oral cavity SmCC typically presents as a rapidly enlarging, firm, submucosal or exophytic mass.[4][17][18]
• Surface ulceration and necrosis are common in advanced lesions.[4]
• Reported intraoral sites include the gingiva, buccal mucosa, retromolar trigone, and palate.[4][17][18]
• Salivary gland SmCC most often involves the parotid gland, followed by the submandibular gland, presenting as a painless or painful enlarging mass.[12][16][19]
• Symptoms depend on location and may include pain, swelling, bleeding, tooth mobility, paresthesia or numbness (particularly of the inferior alveolar nerve when the mandible is involved), trismus, and dysphagia.[17][18][20]

Tempo and Complications

• Growth is characteristically rapid, with tumor doubling times shorter than those of squamous cell carcinoma.[1][18]
• Regional lymph node metastasis is present at diagnosis in a substantial proportion of cases.[2][8]
• Distant metastasis — most commonly to lung, liver, bone, and brain — occurs early; approximately 60% of patients develop distant metastasis within three years.[2]
• The majority of patients present with advanced-stage disease (stage III–IV).[3][7][8]

Red Flags

• A rapidly growing oral or salivary mass in an older patient with a smoking history should raise suspicion for high-grade neuroendocrine carcinoma.
• New-onset lower lip paresthesia (numb chin syndrome) in the setting of a jaw mass warrants urgent evaluation for malignancy.[21]

Dental radiographic findings of SmCC in the oral and maxillofacial region are derived almost entirely from case reports and small series, reflecting the extreme rarity of this tumor at these sites. No imaging feature is pathognomonic; findings overlap broadly with other aggressive malignancies.[6]

Location and Distribution

• When arising from oral mucosa (gingiva, buccal mucosa, retromolar trigone), the primary mass is a soft-tissue lesion that may or may not involve underlying bone.[4][17]
• Gingival primaries are most often reported in the posterior mandible.[17][22]
• Salivary gland SmCC appears as a mass within or adjacent to the parotid or submandibular gland and is generally not visible on intraoral radiographs unless it secondarily invades the mandible.[12][16]
• Metastatic SmCC (usually from a pulmonary primary) may present as an intraosseous jaw lesion, with the mandibular body and ramus being the most common sites.[23][24]

Periphery and Shape

• When bone is involved, the margins are characteristically ill-defined and irregular, reflecting the aggressive, infiltrative growth pattern.[6][20]
• A well-defined periphery is uncommon but has been described in rare gingival primaries without bony invasion.[17]

Internal Architecture

• Intraosseous involvement produces a radiolucent, osteolytic pattern without internal mineralization or calcification.[6][20][25]
• A moth-eaten or permeative pattern of bone destruction is characteristic when the tumor invades the jaws, similar to other high-grade malignancies.[20][25]
• No matrix calcification, ground-glass opacity, or mixed radiolucent-radiopaque pattern is expected.

Effects on Teeth and Adjacent Structures

• Tooth displacement, root resorption, and loss of the lamina dura may occur when the tumor involves the alveolar process.[20]
• Widening of the periodontal ligament space adjacent to the mass has been reported in gingival primaries.[17]
• Inferior alveolar canal widening or destruction may be seen when the mandibular body is involved, correlating with clinical paresthesia.[21]

Growth Pattern, Cortical Involvement, and Extent

• SmCC demonstrates aggressive, infiltrative growth with early cortical destruction and extension into adjacent soft tissues.[1][25]
• Cortical perforation with periosteal reaction may be visible on panoramic or periapical radiographs in advanced cases.[26]
• Expansion of the jaw is generally limited compared with the degree of bone destruction, distinguishing SmCC from slower-growing odontogenic lesions.
• On panoramic radiography, the lesion may mimic other aggressive processes such as osteosarcoma, lymphoma, or metastatic carcinoma.[20]

Recognized Variants and Patterns on CBCT

• CBCT, when obtained, may better delineate the extent of cortical destruction, the three-dimensional relationship of the mass to the mandibular canal, and early periosteal changes that are difficult to appreciate on two-dimensional radiographs.[27][28]
• The internal architecture on CBCT remains purely lytic without mineralized components.
• No specific CBCT pattern distinguishes SmCC from other high-grade malignancies involving the jaws.

Contrast-Enhanced CT

• CT with contrast is the primary cross-sectional modality for evaluating the extent of the primary tumor, cortical bone erosion, and cervical lymphadenopathy.[27][29]
• SmCC typically appears as a homogeneously or mildly heterogeneously enhancing soft-tissue mass that is isodense to mildly hyperdense relative to muscle on unenhanced images.[6][25]
• Bone destruction on CT shows a moth-eaten or permeative pattern; calcification within the mass is characteristically absent.[25]
• In paranasal sinus SmCC, CT demonstrates sinus expansion with bony absorption or sclerosis and aggressive invasion of adjacent compartments.[25][30]

MRI

• MRI provides superior soft-tissue contrast for assessing bone marrow invasion, perineural tumor spread, and skull base involvement.[27][29]
• SmCC is typically isointense on T1-weighted and isointense to mildly hyperintense on T2-weighted sequences, with mild-to-moderate homogeneous enhancement.[25]
• Cystic or necrotic areas and hemorrhage may be present in larger tumors.[30]
• Restricted diffusion (low ADC values, mean ~0.7 × 10⁻³ mm²/s) has been reported in paranasal sinus SmCC, reflecting high cellularity.[30]

FDG-PET/CT

• FDG-PET/CT is recommended for staging locoregionally advanced or high-grade neuroendocrine carcinomas of the head and neck to evaluate for distant metastases.[27]
• SmCC demonstrates intense FDG avidity (high SUV), consistent with its high proliferative rate.[4]
• Brain MRI should be additionally obtained because FDG-PET/CT cannot reliably exclude brain metastasis in high-grade neuroendocrine carcinomas.[27]
• SSTR-based imaging (e.g., ⁶⁸Ga-DOTATATE PET/CT) is not part of the routine evaluation of poorly differentiated NECs.[10]

The differential diagnosis of SmCC in the jaws centers on distinguishing it from other aggressive malignancies that produce ill-defined osteolytic destruction or rapidly growing soft-tissue masses in the oral and maxillofacial region. Definitive distinction requires biopsy with immunohistochemistry.

The highest-risk diagnostic pitfall is misclassifying SmCC as poorly differentiated squamous cell carcinoma, which would lead to inappropriate treatment. A panel including synaptophysin, chromogranin A, INSM1, and cytokeratins (with high-molecular-weight CK 5/6 and 34βE12 to exclude basaloid SCC) should be applied to any undifferentiated small round cell malignancy of the oral cavity or jaws.[32][33][37]

Microscopic Features

• SmCC is composed of sheets, nests, and trabeculae of small cells with scant cytoplasm, high nuclear-to-cytoplasmic ratio, finely granular ("salt-and-pepper") chromatin, and absent or inconspicuous nucleoli.[17][32]
• Cells are round, oval, or spindle-shaped with nuclear molding.[32]
• Mitotic activity is high (>10 mitoses per 2 mm²), and necrosis — often extensive — is characteristic.[10][32]
• Combined SmCC (with a squamous, adenocarcinoma, or large cell neuroendocrine component) may occur.[32][38]

Immunohistochemistry

• Neuroendocrine markers: synaptophysin, chromogranin A, INSM1, and CD56 are the principal markers; the majority of SmCCs are positive for at least two.[10][32][37]
  • INSM1 has demonstrated excellent sensitivity (~96%) and specificity (~98%) for neuroendocrine differentiation in head and neck tumors and may serve as a first-line standalone marker.[37]
  • CD56 is sensitive but relatively nonspecific.[39]
• Cytokeratins: positive for broad-spectrum keratins (AE1/AE3, CAM5.2), often with a paranuclear dot-like pattern; typically negative or only focally positive for high-molecular-weight CK 5/6 and 34βE12.[32][33]
• CK20: positive in approximately 73% of salivary gland SmCCs, often with a paranuclear dot pattern, suggesting biological relatedness to Merkel cell carcinoma; CK20 positivity correlates with improved survival.[12][40]
• TTF-1: positive in a variable proportion of extrapulmonary SmCCs and therefore cannot reliably distinguish a pulmonary metastasis from a primary head and neck SmCC.[32][41]
• Ki-67 proliferative index is typically 50%–100%, which is helpful in distinguishing SmCC from carcinoid tumors.[32]
• Loss of RB1 expression and aberrant p53 staining (overexpression or null pattern) are common in high-grade NECs and help distinguish them from well-differentiated NETs.[32]

Molecular Features

• TP53 and RB1 mutations are the most frequently identified genomic alterations, though at lower prevalence than in SCLC, suggesting biological heterogeneity across anatomic sites.[15]
• PIK3CA-pathway alterations, NOTCH1 mutations, and rare FGFR3-TACC3 fusions have been identified and may represent potential therapeutic targets.[15]

Radiologic-Pathologic Correlation

The aggressive, ill-defined osteolytic pattern on imaging corresponds to the diffuse infiltrative growth and high mitotic activity seen histologically. The absence of calcification or matrix production on imaging reflects the purely epithelial, non-matrix-producing nature of the tumor.

Workup and Referral

• Biopsy with immunohistochemistry is essential for diagnosis.[4][10]
• Staging workup should include contrast-enhanced CT or MRI of the head and neck, chest CT, and FDG-PET/CT for locoregionally advanced disease.[10][27]
• Brain MRI should be obtained given the propensity for cerebral metastasis in high-grade NECs.[27]
• Molecular profiling of tumor tissue is recommended for patients with unresectable or metastatic disease to identify actionable alterations.[10]
• Multidisciplinary tumor board evaluation is critical.[3][4]

Treatment

Treatment is extrapolated from SCLC and extrapulmonary NEC protocols, as no randomized trials exist for head and neck SmCC.[1][4][5]

• Resectable disease: surgical resection with adjuvant platinum-etoposide chemotherapy ± radiotherapy; alternatively, neoadjuvant chemotherapy followed by surgery.[10]
• Locoregionally advanced / unresectable disease: definitive concurrent chemoradiation with cisplatin (or carboplatin) plus etoposide is the standard approach. Four cycles of chemotherapy are typically administered.[4][5][10][32]
• Metastatic disease: systemic platinum-etoposide chemotherapy.[5][10][42]
• The addition of surgery to chemoradiation has not demonstrated a survival advantage in locally advanced head and neck SmCC.[3]
• Immune checkpoint inhibitors combined with chemotherapy remain investigational for extrapulmonary poorly differentiated NECs.[10]

Prognosis

• Overall five-year survival for head and neck SmCC is approximately 27%, significantly worse than squamous cell carcinoma of the same region.[7][8]
• Median overall survival for oral cavity SmCC is approximately 20 months.[3]
• Salivary gland SmCC may carry a somewhat better prognosis than SmCC at other head and neck sites, with five-year survival of approximately 37–46%, particularly for CK20-positive (Merkel cell type) tumors.[12][16][19][40]
• Distant metastasis is the predominant cause of death.[2][43]

Prognostic Factors

• Tumor size >3 cm, advanced nodal stage (N2+), presence of distant metastasis, and CK20-negative immunophenotype are associated with worse outcomes.[8][12][16]
• Receipt of chemotherapy is an independent favorable prognostic factor.[8]

Surveillance

• For resected disease: clinical and imaging follow-up every 12 weeks for the first year, then every 6 months, with appropriate cross-sectional imaging.[10]
• For unresectable/metastatic disease on treatment: imaging every 6–16 weeks.[10]